title: Better outcome of HBe Ag (-) than HBe Ag (+) lamivudine treatment of HBV chronically infected patients.
abstract: From May 2006 to December 2007 in Warsaw Hospital for Infectious Diseases one hundred and eight patients chronically infected HBV were treated with lamivudine. Among them 46 (42.5%) were HBeAg (+) and 62 (57.5%) HBeAg (-). HBV DNA levels were analysed in weeks 24, 48 and 72 of therapy using Real Time HBV PCR (Abbott) with a limit of detection of 28 copies/ml. Complete response for treatment was defined as HBV VL of less than 10(2) copies/ml (group A). Partial response was defined as HBV VL ranging from 10(2) to 10(5) copies/ml (group B), and treatment failure was determined by HBV VL above 10(5) copies/ml (group C). Presented results confirmed better response to lamivudine treatment in patients HBeAg (-) than HBeAg (+).
authors.affiliation: Oddział Dzienny, Wojewódzki Szpital Zakaźny w Warszawie. anna.rzadzka@gmail.com
authors.forename: Anna
authors.initials: A
authors.lastname: Kołakowska-Rzadzka
authors.forename: Hanna
authors.initials: H
authors.lastname: Berak
authors.forename: Janusz
authors.initials: J
authors.lastname: Stańczak
authors.forename: Tomasz
authors.initials: T
authors.lastname: Dyda
authors.forename: Andrzej
authors.initials: A
authors.lastname: Horban
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006513:Hepatitis B e Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D011044:Poland; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D019259:Lamivudine